{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6ab30ec0f98781f91da1d58c?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What is the current clinical evidence for tandem CAR T-cell therapies in R/R DLBCL? ","description":"<p>The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? </p><p><br></p><p>This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}